ImmunoACT
- ImmunoACT, supported by IIT-Bombay and Laurus Labs, has received approval from the Central Drugs Standard Control Organization (CDSCO) for India's first CAR-T cell therapy, NexCAR19 (Actalycabtagene autoleucel), designed for the treatment of relapsed/refractory (r/r) B-cell lymphomas and leukemia.
- NexCAR19 is a humanized CD19-targeted Chimeric Antigen Receptor T cell (CAR-T cell) therapy, the first of its kind to be developed in India, representing a significant advancement in cell-and-gene therapies.
- Laurus Labs, a pharmaceutical company, invested over $18 million in ImmunoACT to support its research and development, aiming to make CAR-T therapy accessible and affordable in India and other resource-constrained settings.
- The approval of ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 President Droupadi Murmu Visits Slovakia
- 2 Iran and U.S. Hold Constructive Nuclear Talks in Oman
- 3 India and Nepal Strengthen Customs Cooperation
- 4 15th BRICS Agriculture Ministers Meeting in Brazil
- 5 India, US Hail Progress on New Trade Deal
- 6 Beryl, Helene, Milton, and John Retired from Hurricane Name Lists
- 7 Similipal Declared Odisha’s Second National Park
- 8 India Opens New Frontiers in Himalayan Climate Research
- 9 Rare Sighting of Juvenile Colossal Squid in South Atlantic
- 10 Record Low Snow Persistence in Hindu Kush Himalaya Region
